Sight Sciences

Meet our colleague, Michael Canda, COA, who we would like to recognize for embodying our values of collaboration and passion for our work. Thank you, Michael, for your outstanding contributions! "Working at Sight Sciences in sales in the Ocular Surface Division for the past three years has been a rewarding experience. Our culture fosters innovation and collaboration, allowing me to continually learn and grow professionally. The transformative technology we work with keeps me engaged, and the talented, supportive team creates a positive and motivating environment. Work truly becomes enjoyable when you love what you do!" said Michael. Here’s to many more milestones together as we continue to reimagine eyecare with transformative technology and an interventional mindset! #EmployeeSpotlight #SightSciences #SightSciencesTeam

Special recognition goes to our Director of Medical Affairs, Alison Harvey, Ph.D., MS, for her exceptional contributions at the Women in Ophthalmology meeting. Alison co-authored four posters and presented significant findings. Congratulations on this remarkable achievement, Alison, and a heartfelt thank you to all the contributing authors! The four posters are: 36-Month Outcomes for Canaloplasty and Trabeculotomy Combined with Cataract Surgery: Extended Follow-up from the GEMINI Study Noureen Khan, MD; Alison E. Harvey, PhD, MS Standalone Canaloplasty and Trabeculotomy in Pseudophakic Eyes with Primary Open-Angle Glaucoma: Prospective, Multicenter, 24-Month Outcomes Anita Campbell, MD; Alison E. Harvey, PhD, MS Tear Break-up, Meibomian Gland, and Dry Eye Symptoms Improvement for Cyclosporine-Treated Patients After Localized Heat Therapy Treatment Yuna Rapoport, MD, MPH, Alison E. Harvey, PhD, MS Localized Heat Therapy Compared to Cyclosporine Ophthalmic Emulsion: A Subanalysis on Age, Gender, and Disease Burden Alison E. Harvey, PhD, MS; Jaime Dickerson, PhD #wio2024 #womeninophthalmology #glaucoma #womenineyecare #ophthalmology #omnisurgucal #tearcare #tearcaresystem

A big thank you to Dr. Noureen Khan for studying our OMNI technology and presenting her findings at the Women in Ophthalmology meeting last Saturday. Her poster was titled “36-Month Outcomes for Canaloplasty and Trabeculotomy Combined with Cataract Surgery: Extended Follow-up from the GEMINI Study.” At #WIO2024, she also spoke with Healio | Ocular Surgery News about the study results, and the video will be published soon. Congratulations, Dr. Khan! www.omnisurgical.com #ophthalmology #glaucoma #omnisurgical

Two days filled with many demos, wet labs, poster presentations, and insightful discussions on our OMNI, SION, and TearCare technologies at #WIO2024 in Southern California! Supporting and participating in the Women in Ophthalmology meeting is always a pleasure. A big thank you to everyone for your collaboration and continued partnership!

#ESCRS2024 is just around the corner, and we are looking forward to showcasing how the OMNI® Surgical System is transforming #glaucoma care. Join us on September 6-9 at Booth C7.12 in Hall 7 for live demos, and see OMNI in action at the MIGS Masterclass and the #MIGS Without Implants Wet Lab. Our team—including Rob Hill, Nick Smith, and Stephen Mitchley—will be there to answer all your questions. See you in Barcelona! https://lnkd.in/garUtwjj

We are excited to welcome Peter Marzano as our new Vice President, Business Leader, Surgical Glaucoma! With over 22 years of experience in the medical technology and surgical industries, Pete brings a wealth of knowledge and leadership.   “I am thrilled to join Sight Sciences and work alongside a talented team. Together, we will push forward our mission of developing transformative interventional technologies that allow eyecare providers to elevate the standards of care—empowering people to keep seeing,” said Pete.   Matt Link, our Chief Commercial Officer, adds, “We are excited to have Pete join Sight Sciences as we scale our Surgical #Glaucoma business. Pete’s leadership will be pivotal as we grow and build the infrastructure needed for sustained success.”   Pete’s notable career includes key sales and leadership roles at Stryker, Johnson and Johnson, and most recently at NuVasive. During his 18 years at NuVasive, the company grew from less than 100 million dollars in revenue to over 1.2 billion dollars globally, becoming the largest spine-focused company in the world. He has excelled in executive roles across sales management, global training and development, market development, and most recently as Vice President, Europe, Middle East, and Africa (EMEA), where he led the region to record growth and profitability.   Welcome to Sight Sciences, Pete! We look forward to the journey ahead in elevating standards of care in #ophthalmology and #optometry.

Our Ocular Surface Disease (OSD) team conducted an in-depth analysis of the SAHARA RCT data with the MUSC Storm Eye team. The twelve-month results of the SAHARA RCT were recently published, demonstrating improved signs and symptoms of Dry Eye Disease for TearCare patients crossed over from Restasis. The results show that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when our TearCare technology is used as a primary or secondary treatment for dry eye disease. More about the Sahara RCT here: https://lnkd.in/gHRPGaFm . . . . . . . . . . The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events. #sightsciences #treacare #dryeye #saharastudy #sahararct

Our VP of Marketing, H. B. Pierre Simon Jr., recently shared insights with Xtalks on the latest advancements in eye care technology. Pierre discussed how Sight Sciences is at the forefront of eye care revolution, building a strong portfolio to address both current and future needs in #glaucoma and #dryeye intervention Read the full interview here: https://lnkd.in/ggZuyNzs

The DOC Congress in Nuremberg, Germany, has been a fantastic experience! We have had great discussions about the power of our OMNI® Surgical System and the benefits of interventional glaucoma and implant-free MIGS. Today is the final day of the exhibition, and we look forward to connecting with you!

Our team in Germany looks forward to meeting you at the DOC Congress! Visit our booth to explore the benefits of interventional glaucoma and implant-free MIGS, and discover the latest clinical studies on our OMNI® Surgical System.